GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Cyclically Adjusted Revenue per Share

Viatris (LTS:0A5V) Cyclically Adjusted Revenue per Share : $22.50 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Viatris Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Viatris's adjusted revenue per share for the three months ended in Mar. 2024 was $3.029. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $22.50 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Viatris's average Cyclically Adjusted Revenue Growth Rate was -3.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Viatris was 27.20% per year. The lowest was 2.60% per year. And the median was 14.20% per year.

As of today (2024-05-18), Viatris's current stock price is $11.125. Viatris's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $22.50. Viatris's Cyclically Adjusted PS Ratio of today is 0.49.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viatris was 5.23. The lowest was 0.37. And the median was 1.64.


Viatris Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Viatris's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Cyclically Adjusted Revenue per Share Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.00 17.13 22.32 22.58 22.43

Viatris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.95 22.73 23.11 22.43 22.50

Competitive Comparison of Viatris's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PS Ratio falls into.



Viatris Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viatris's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.029/131.7762*131.7762
=3.029

Current CPI (Mar. 2024) = 131.7762.

Viatris Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.623 100.560 6.058
201409 5.245 100.428 6.882
201412 5.198 99.070 6.914
201503 4.217 99.621 5.578
201506 4.544 100.684 5.947
201509 5.244 100.392 6.883
201512 4.884 99.792 6.449
201603 4.300 100.470 5.640
201606 5.024 101.688 6.511
201609 5.839 101.861 7.554
201612 6.092 101.863 7.881
201703 5.065 102.862 6.489
201706 5.516 103.349 7.033
201709 5.563 104.136 7.040
201712 6.045 104.011 7.659
201803 5.194 105.290 6.501
201806 5.439 106.317 6.741
201809 5.542 106.507 6.857
201812 5.961 105.998 7.411
201903 4.846 107.251 5.954
201906 5.532 108.070 6.746
201909 5.738 108.329 6.980
201912 6.144 108.420 7.468
202003 5.066 108.902 6.130
202006 5.281 108.767 6.398
202009 5.741 109.815 6.889
202012 4.241 109.897 5.085
202103 3.669 111.754 4.326
202106 3.787 114.631 4.353
202109 3.741 115.734 4.260
202112 3.590 117.630 4.022
202203 3.455 121.301 3.753
202206 3.382 125.017 3.565
202209 3.348 125.227 3.523
202212 3.174 125.222 3.340
202303 3.093 127.348 3.201
202306 3.256 128.729 3.333
202309 3.264 129.860 3.312
202312 3.169 129.419 3.227
202403 3.029 131.776 3.029

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Viatris  (LTS:0A5V) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Viatris's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=11.125/22.5
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viatris was 5.23. The lowest was 0.37. And the median was 1.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Viatris Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Viatris's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris (LTS:0A5V) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Cyclically Adjusted Revenue per Share
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (LTS:0A5V) Headlines

No Headlines